MHRA
- Local brand name: Yorvipath
- Status: approved
Yorvipath (PALOPEGTERIPARATIDE) regulatory status in United Kingdom.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MHRA has authorised it.
Ascendis Pharma Bone is the originator. The local marketing authorisation holder may differ — check the official source linked above.